Exavir Therapeutics Announces Entry Into a Litigation Settlement and License Agreement For Ultra-Long-Acting HIV Compounds With ViiV Healthcare
May 22 2024 - 7:40AM
Business Wire
- ViiV Healthcare will make upfront and milestone payments as
well as tiered low-to-mid single digit royalties on future sales of
ultra-long-acting HIV compounds
Today, Exavir Therapeutics announced that the company has
entered into a settlement and license agreement with ViiV
Healthcare for ultra-long-acting HIV compounds. As part of the
agreement, Exavir will receive an upfront and milestone payments,
as well as low-to-mid single digit royalties on future sales.
Exavir Therapeutics is focused on discovering and developing
ultra-long-acting therapeutics with best-in-class product profiles.
The company uses its proprietary prodrug and formulation technology
to develop novel extended half-life therapeutics with potential for
dosing as infrequent as once-every-six-months or even
once-a-year.
“We are excited to reach an agreement with the scientific and
market leader in long-acting injectables for HIV. We look forward
to the continued success of ViiV Healthcare in their efforts to
discover and develop more convenient and effective therapies for
people living with HIV or at risk of acquiring HIV,” said Alborz
Yazdi, co-founder and CEO of Exavir.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522307113/en/
Exavir Info media@exavirtx.com